Medical Professionals Reference (MPR)Cardamyst Nasal Spray Now Available for Self-Treatment of PSVT Episodes

The FDA approved the first self-administered nasal spray for acute PSVT conversion, enabling patients to treat episodes at home instead of emergency departments. Phase 3 data showed 64% of patients converted to sinus rhythm within 30 minutes vs. 31% placebo with a median time of 17.2 minutes.

⚖️ PROFESSIONAL IMPACT

• Paradigm shift from ED-dependent PSVT management to patient self-treatment reduces emergency visits and healthcare utilization costs
• Intranasal calcium channel blocker offers alternative to vagal maneuvers and adenosine, particularly for patients with recurrent episodes
• Nasal delivery requires sitting position due to dizziness/syncope risk. Patient education critical to prevent injury during administration.
• Second dose permitted 10 minutes after initial treatment if symptoms persist. Seek medical help if no improvement 20 minutes post-second dose.

🎯 ACTION ITEMS

• Identify PSVT patients with frequent episodes who could benefit from home treatment option
• Educate patients on proper sitting position requirement and two-dose protocol with timing guidelines
• Counsel on common nasal adverse effects: discomfort, congestion, rhinorrhea, throat irritation, epistaxis
• Document copay assistance program availability with $25 cap for commercially insured eligible patients

More in Cardiac Arrhythmia